The HBsAg rapid test is a point-of-care lateral-flow immunoassay that detects hepatitis B surface antigen in blood, serum, or plasma. It delivers quick screening results (usually within 15–30 minutes) to indicate current hepatitis B infection (acute or chronic). Reactive results should be confirmed by laboratory tests (e.g., ELISA or nucleic acid testing) for diagnosis and management.

A positive HBsAg (hepatitis B surface antigen) test means hepatitis B virus is present in the blood and the person is currently infected and potentially infectious. It can indicate acute or chronic infection; further tests (anti‑HBs, anti‑HBc IgM, HBV DNA) and clinical assessment determine stage and treatment needs. Vaccination produces anti‑HBs, not HBsAg. Follow-up with a healthcare provider is recommended.

The HBsAg rapid test is qualitative; the normal (expected) result is non‑reactive/negative—no detectable hepatitis B surface antigen. A reactive/positive result indicates HBsAg presence, suggesting acute or chronic infection and requires confirmatory laboratory testing (ELISA or PCR). False negatives can occur during the window period, so follow local guidelines for repeat and confirmatory testing.

HBsAg (Hepatitis B surface antigen) test costs vary by country and provider. In India private labs typically charge about ₹200–600; in the US prices commonly run around $20–100 at commercial labs; in the UK NHS testing is usually free through public clinics while private testing may be £10–50. Costs depend on location, lab, and whether testing is done through public health services or insurance.

HBsAg rapid (point-of-care) tests typically give results within 15–30 minutes, with many kits read at about 15–20 minutes. A reactive result should be confirmed by laboratory testing (ELISA and/or PCR), which can take a few days to return. Note there is a window period, so repeat or additional testing may be recommended by your clinician.

HBsAg is the hepatitis B surface antigen indicating current hepatitis B infection. The antigen itself is a marker, but active HBV infection can cause liver inflammation and impaired function, shown by elevated ALT/AST; chronic infection increases risk of fibrosis, cirrhosis and hepatocellular carcinoma. Regular monitoring and antiviral treatment can suppress replication and help preserve liver function.